Mogamulizumab (Poteligeo®) is indicated for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||21/12/2020|
|Rapid review completed||14/01/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||27/01/2021|
|Pre-submission consultation with Applicant||23/03/2021|
|Current Status||Awaiting HTA submission from Applicant|